names of glp-1 drugs glp 1 oral list List current and its analogs [36-39] complete list of glp 1

GLP-1 receptor expression in human tumors and human normal tissues: Potential for in vivo targeting

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

Which of the GLP-1-based therapies can achieve the most desirable weight loss balanced with a manageable safety profile (e.g., GI events) and favorable dosing schedule

Structure's GLP-1 Pill Could Be Big, But Trial Results Will Confirm Structure Therapeutics Today GPCR Structure Therapeutics $48.48 +2.45 (+5.32%) As of 07/17/2026 04:00 PM Eastern 52-Week Range $15.80 $94.90 Price Target $110.55 Shares of Structure Therapeutics NASDAQ: GPCR have far outperformed both of the companies above in the last year, rising by over 150% during that time as investors have grown enthusiastic about aleniglipron, the firm's GLP-1 agonist candidate

Diab Metab J

Nephrologists defined their ideal patient as someone with diabetic kidney disease exhibiting persistently elevated urinary albumin-to-creatinine ratio (ACR) or decline in eGFR with proper reninangiotensinaldosterone system (RAAS) blockade, starting with SGLT2is first and subsequently adding GLP1-RAs